|This Slide: #75 of 100|
Slide #75. Charles River Laboratories — CRO Services Division of Galapagos NV
Charles River Laboratories (NYSE:CRL)
CRO Services Division of Galapagos NV
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has entered into a definitive agreement to acquire the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. These businesses are global leaders in integrated drug discovery services, with a predominant focus on in vitro capabilities. The acquisition will position Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.
Charles River Laboratories International is a contract research organization. Co. has a laboratory animal medicine and science to develop a portfolio of discovery and safety assessment services. Co.'s segments include: Research Models and Services, which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides DSA services, including in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development; Manufacturing Support, which ensure the safe production and release of products manufactured by Co.'s clients.
CRL SEC Filing Email Alerts Service
Open the CRL Page at The Online Investor »
Strong Buy (3.75 out of 4)